Otolaryngology Doctors in Pittsfield, MA Accepting Medicare

4 Otolaryngology doctors found. Showing 1 - 4

John Anthony Loiodice, M.D., F.A.C.S. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 510 North St, Suite One, Pittsfield, MA 01201 Phone: 413-448-8291    Fax: 413-447-9040

Michael A. Stamm, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 510 North St Ste 10, Pittsfield, MA 01201 Phone: 413-448-8291    Fax: 413-447-9040

Dr. Giulio Isidoro Cavalli, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 195 South St, Pittsfield, MA 01201 Phone: 413-443-6116    Fax: 413-443-9099

Ann Marie Visconti, PAC Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 294 First Street, Pittsfield, MA 01201 Phone: 413-341-1889    Fax: 413-344-4747

News Archive

PPD, Inc. has announced the launch of PPD Medical Device Division

PPD, Inc. has announced the launch of PPD Medical Device, a division of PPD Development, providing services to the medical device industry with experience in developing stents, devices and therapies in the areas of interventional cardiology, endovascular, neurology and orthopedic disorders as well as wound care.

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21").

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

Lung cancer mortality could be reduced by including smoking cessation with screening

Including smoking cessation with existing lung cancer screening efforts would reduce lung cancer mortality by 14 percent and increase life-years gained by 81 percent compared with screening alone, according to a study from Rafael Meza from the University of Michigan and colleagues and published in the Journal of Thoracic Oncology, a publication of the International Association for the Study of Lung Cancer.

FDA licenses NYBC's HEMACORD stem cell product

The Food and Drug Administration has licensed HEMACORD for allogeneic hematopoietic (blood-forming) stem cell transplantation, the first such approval of a stem cell product in the world.

Read more Medical News

› Verified 1 days ago